Peresolimab Promising for RA

No serious adverse events were reported. Peresolimab had a good safety and tolerability profile.

Conclusion

The results of this study show that stimulating the PD-1 receptor with peresolimab has the potential to treat RA. Further research may increase the number of pharmaceutical agents available to manage autoimmune diseases.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Tuttle J, Drescher E, Simón-Campos J, et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis [abstract: L03]. Arthritis Rheumatol. 2022 Oct; 74(suppl 9).
A study of LY3462817 in participants with rheumatoid arthritis (NCT04634253). ClinicalTrials.gov. 2023 Feb 1.

Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights

Strategies to identify and track remission in your RA patients

A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Conclusion

References

ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

Target Remission

Remission Definitions in RA: Common Questions & Implications for Clinical Practice

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Conclusion

References

Related Articles